BACKGROUND: Accurate staging and identification of optimal candidates for local salvage therapy, such as salvage radical prostatectomy (SRP), is necessary to ensure optimal care in patients with radiorecurrent prostate cancer (PCa). We aimed to analyze performance of magnetic resonance imaging (MRI) and prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/computed tomography (CT) for predicting pathologic nonorgan confined disease (pT3) and lymph node involvement (pN+) in patients treated with SRP for radiorecurrent PCa. METHODS: We retrospectively reviewed the institutional database to identify patients who underwent MRI or 68 Ga-PSMA-PET/CT before SRP for radiorecurrent PCa. The diagnostic estimates of MRI and PSMA-PET/CT for pT3 and pN+, were calculated. RESULTS: We identified 113 patients with radiorecurrent PCa who underwent preoperative MRI followed by SRP; 53 had preoperative 68 Ga-PSMA-PET/CT. For the detection of pT3 disease, the overall accuracy of MRI was 70% (95% confidence interval [CI] 61-78), sensitivity 40% (95% CI 26-55) and specificity 94% (95% CI 85-98); PSMA-PET/CT had slightly higher accuracy of 77% (95% CI 64-88), and higher sensitivity of 90% (95% CI 68-99), but lower specificity of 70% (95% CI 51-84). For pN+ disease, MRI had poor sensitivity of 14% (95% CI 3-36), specificity of 50 (95% CI 39-61) and total accuracy of 43% (95% CI 34-53); PSMA-PET/CT had an accuracy of 85% (95% CI 72-93), sensitivity of 27% (95% CI 6-61), and specificity of 100% (95% CI 92-100). CONCLUSION: In patients with radiorecurrent PCa, both, MRI, and 68 Ga-PSMA PET/CT are valuable tools for the pre-SRP staging and should be integrated into the standard workup. For lymph node metastases, 68 Ga-PSMA PET/CT is a strong rule-in test with nearly perfect specificity; in contrast MRI had a low accuracy for lymph node metastases.

Department of Nuclear Medicine University Hospital Cologne Cologne Germany

Department of Radiology University Hospital Cologne Cologne Germany

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Medical University of Silesia Zabrze Poland

Department of Urology Medical University of Vienna Vienna Austria

Department of Urology University of Texas Southwestern Dallas Texas USA

Department of Urology Uro Oncology Robot Assisted and Specialized Urologic Surgery University Hospital Cologne Cologne Germany

Department of Urology Weill Cornell Medical College New York New York USA

Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

See more in PubMed

Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80-82. doi:10.1001/jama.2015.6036

Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967-987. doi:10.1016/j.eururo.2018.10.011

Zumsteg ZS, Spratt DE, Romesser PB, et al. Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J Urol. 2015;194(6):1624-1630. doi:10.1016/j.juro.2015.06.100

Jansen BHE, van Leeuwen PJ, Wondergem M, et al. Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix criteria for biochemical recurrence after curative radiotherapy. Euro Urol Oncol. 2021;4(5):821-825. doi:10.1016/j.euo.2020.01.002

Nestler T, Wittersheim M, Schaefer S, et al. Prediction of radioresistant prostate cancer based on differentially expressed proteins. Urol Int. 2021;105(3-4):316-327. doi:10.1159/000509447

Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263-282. doi:10.1016/j.eururo.2020.09.046

Valle LF, Lehrer EJ, Markovic D, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol. 2021;80(3):280-292. doi:10.1016/j.eururo.2020.11.010

Pokala N, Huynh DL, Henderson AA, Johans C. Survival outcomes in men undergoing radical prostatectomy after primary radiation treatment for adenocarcinoma of the prostate. Clin Genitourin Cancer. 2016;14(3):218-225. doi:10.1016/j.clgc.2015.12.010

Grubmüller B, Jahrreiss V, Brönimann S, et al. Salvage radical prostatectomy for radio-recurrent prostate cancer: an updated systematic review of oncologic, histopathologic and functional outcomes and predictors of good response. Curr Oncol. 2021;28(4):2881-2892. doi:10.3390/curroncol28040252

Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol. 2010;57(3):437-445. doi:10.1016/j.eururo.2009.02.041

Yokomizo A, Wakabayashi M, Satoh T, et al. Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, phase 3 trial (JCOG0401)†. Eur Urol. 2020;77(6):689-698. doi:10.1016/j.eururo.2019.11.023

Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol. 2012;61(5):961-971. doi:10.1016/j.eururo.2012.01.022

Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60(2):205-210. doi:10.1016/j.eururo.2011.03.011

Marra G, Karnes RJ, Calleris G, et al. Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: a multicenter retrospective study. Urol Oncol. 2021;39(5):296.e21-296.e29. doi:10.1016/j.urolonc.2020.11.002

Rajwa P, Schuettfort VM, Quhal F, et al. Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. World J Urol. 2021;39(10):3771-3779. doi:10.1007/s00345-021-03715-4

Quhal F, Rajwa P, Mori K, et al. The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. Prostate. 2021;81(11):765-771. doi:10.1002/pros.24173

Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol. 2010;22(1):46-55. doi:10.1016/j.clon.2009.10.015

Afshar-Oromieh A, Vollnberg B, Alberts I, et al. Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. Eur J Nucl Med Mol Imaging. 2019;46(11):2289-2297. doi:10.1007/s00259-019-04438-w

Abd-Alazeez M, Ramachandran N, Dikaios N, et al. Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images. Prostate Cancer Prostatic Dis. 2015;18(2):128-136. doi:10.1038/pcan.2014.55

Pfister D, Haidl F, Nestler T, et al. (68) Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer. BJU Int. 2020;126(6):679-683. doi:10.1111/bju.15135

Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243-262. doi:10.1016/j.eururo.2020.09.042

Zattoni F, Kawashima A, Morlacco A, et al. Detection of recurrent prostate cancer after primary radiation therapy: an evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil. Practical Radiation Oncology. 2017;7(1):42-49. doi:10.1016/j.prro.2016.06.003

Kowa JY, Soneji N, Sohaib SA, et al. Detection and staging of radio-recurrent prostate cancer using multiparametric MRI. Br J Radiol. 2021;94(1120):20201423. doi:10.1259/bjr.20201423

Sala E, Eberhardt SC, Akin O, et al. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology. 2006;238(1):176-183. doi:10.1148/radiol.2381052345

Muehlematter UJ, Burger IA, Becker AS, et al. Diagnostic accuracy of multiparametric MRI versus (68)Ga-PSMA-11 PET/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology. 2019;293(2):350-358. doi:10.1148/radiol.2019190687

Ingrosso G, Becherini C, Lancia A, et al. Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis. Euro Urol Oncol. 2020;3(2):183-197. doi:10.1016/j.euo.2018.12.011

Woo S, Ghafoor S, Becker AS, et al. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. Eur J Hybrid Imaging. 2020;4(1):16. doi:10.1186/s41824-020-00085-9

Thalgott M, Düwel C, Rauscher I, et al. One-Stop-Shop Whole-Body (68)Ga-PSMA-11 PET/MRI compared with clinical nomograms for preoperative T and N staging of High-Risk prostate cancer. J Nucl Med. 2018;59(12):1850-1856. doi:10.2967/jnumed.117.207696

Grubmüller B, Baltzer P, Hartenbach S, et al. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res. 2018;24(24):6300-6307. doi:10.1158/1078-0432.CCR-18-0768

Liu W, Fakir H, Randhawa G, et al. Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. Clin Transl Radiat Oncol. 2022;32:41-47. doi:10.1016/j.ctro.2021.11.006

Hope TA, Eiber M, Armstrong WR, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7(11):1635-1642. doi:10.1001/jamaoncol.2021.3771

Panebianco V, Villeirs G, Weinreb JC, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Euro Urol Oncol. 2021;4(6):868-876. doi:10.1016/j.euo.2021.01.003

A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer